Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial carcinoma
MOH_2019-04-22_007095Phase 2Recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempegaldesleukin and nivolumab in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Nektar Therapeutics. Started Feb 2019; status: recruiting.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on MOH_2019-04-22_007095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-22_007095.